Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of Oct. 4, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Shimadzu Scientific Instruments today ... UV-visible spectrophotometer. Offering wavelength scanning from 190 to ... for applications in a variety of industries, including ... user-friendly UV-1280 enables intuitive operation, while the enhanced ...
(Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... July 11 Sigma-Aldrich Corporation,(Nasdaq: SIAL ), ... second,quarter results on Wednesday, July 23, 2008, at ... This call is being webcast by Thomson/CCBN and ... http://www.sigma-aldrich.com ., The webcast is also ...
... Research Inc., (TSX:,ARI), a biotechnology company discovering ... today announced its financial and operational,results for ... May 31st, 2008., "Throughout the second ... anti-cancer antibodies towards human clinical trial. Most ...
... newly developed nano-sized electronic device is an important step ... creation of the universe. This invisible light makes up ... and may provide insights into the earliest stages of ... , The tiny, new circuit, developed by physicsts at ...
Cached Biology Technology:Sigma-Aldrich Corporation's 2nd Quarter 2008 Earnings Conference Call 2ARIUS announces second quarter fiscal 2008 financial results 2ARIUS announces second quarter fiscal 2008 financial results 3ARIUS announces second quarter fiscal 2008 financial results 4ARIUS announces second quarter fiscal 2008 financial results 5ARIUS announces second quarter fiscal 2008 financial results 6ARIUS announces second quarter fiscal 2008 financial results 7ARIUS announces second quarter fiscal 2008 financial results 8ARIUS announces second quarter fiscal 2008 financial results 9ARIUS announces second quarter fiscal 2008 financial results 10ARIUS announces second quarter fiscal 2008 financial results 11ARIUS announces second quarter fiscal 2008 financial results 12ARIUS announces second quarter fiscal 2008 financial results 13ARIUS announces second quarter fiscal 2008 financial results 14ARIUS announces second quarter fiscal 2008 financial results 15Nano-sized electronic circuit promises bright view of early universe 2Nano-sized electronic circuit promises bright view of early universe 3
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)... CIE San Diego has launched an innovative trust network ... care coordination among social service and care providers by enabling ... million grant from the Alliance Healthcare Foundation to expand to ... as a "Live Well San Diego" partner on December 11 ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Survey is partnering with the Chilean government to develop a ... after the historic eruption of Chaitn Volcano on May 2. ... install monitoring networks at Chaitn to transmit data in real ... June 13, the USGS signed a letter of intent with ...
... Northwestern University biomedical engineer who has developed optical technology ... colon cancer has received a $7.5 million grant over ... study an instrument that potentially could become a routine ... trials. Colon cancer is the second-leading cause of ...
... release is available in German . , ... or dissolved metallic salts in high concentrations are detrimental to ... Such conditions destroy proteins, ensuring that all biological functions in ... find at the limits of hostile conditions where we still ...
Cached Biology News:USGS to help Chile develop volcano early warning system 2NCI grant launches clinical trials for colon cancer screening 2NCI grant launches clinical trials for colon cancer screening 3Purple extremist thrives under inhospitable conditions 2Purple extremist thrives under inhospitable conditions 3
... reagent (F-2902) was developed in collaboration with ... measurement of the kinetics of Fc receptor ... directly in the phagovacuole.2 The Fc OxyBURST ... albumin (BSA) that has been covalently linked ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
TACS Apoptotic DNA Laddering Kits are used to assay cells and tissues for apoptosis by...
Biology Products: